Hyderabad-based Natco Pharma Limited has entered into an agreement with Dr Reddy's Laboratories Limited for the development, manufacture and supply of a basket of value-added generic oncology drugs.
The products selected under this collaboration include currently selling oral and injectable innovator products, which have multi-million dollar sales across the globe. One of the products is Paclitaxel, which is a generic version of Abraxane, Natco stated in a press release.
Dr Reddy's and Natco would together develop these products for registration and commercialisation across the globe including the regulated markets of the US and the European Union. Natco will exclusively supply the products to Dr Reddy's.
According to the agreement, Dr Reddy's would pay an undisclosed amount as upfront to Natco for securing rights to the product portfolio and capacity required to manufacture products.
In addition, both parties have a profit sharing mechanism in their respective designated territories.
Dr Reddy's would have exclusive commercialisation rights for certain products worldwide and territory specific commercialisation rights for all other products, including the US and EU.
Both parties would also look to supplement the agreement with future products to expand strategic collaboration. "We are delighted to be working with Dr Reddy's and look forward to a mutually beneficial strategic collaboration," Natco chief operating officer Rajeev Nannapaneni said.